Vertex’s non-opioid painkiller succeeds in late-stage trials, FDA finalizes CAR-T guidance

By PharmaCompass

2024-02-01

Impressions: 969

In Phispers this week, there is news of an experimental non-opioid painkiller from Vertex Pharmaceuticals showing positive results in two late-stage trials. Once approved, it will provide a viable alternative to addictive opioids that have led to thousands of deaths and a crisis in America.

In other news from clinical trials, BMS’ Opdivo failed to meet its primary endpoint of disease-free survival in patients with localized renal cell carcinoma who have a high risk of relapse after surgery. A day earlier, Merck’s Keytruda showed remarkable clinical benefit for the very same indication.

After mandating a serious “boxed warning” on several CAR-T therapies last week, the United States Food and Drug Administration (FDA) has finalized a guidance on how sponsors may go about getting such therapies approved.

Pfizer managed to surprise markets by eking out a profit of US$ 593 million in the fourth quarter (Q4) of 2023 when analysts were expecting a 10-figure loss.

In deals, 2seventy Bio has decided to sell all its preclinical and clinical programs to Regeneron. It will now focus on commercializing its CAR-T therapy Abecma. Meanwhile, Biogen has ended a post-approval study of its Alzheimer’s drug Aduhelm to focus on its other drug for the disease — Leqembi — which bagged FDA approval last year.

Vertex’s non-opioid painkiller succeeds in two late-stage trials

Vertex Pharmaceuticals’ non-opioid painkiller VX-548 met its primary goals in two late-stage trials, marking a major development in a decades-long effort to have an alternative to opioids. The experimental non-opioid painkiller reduced acute, post-surgical pain. It was found to be safe, and did the job without the risk of addiction.

The opioid crisis in America has claimed over 645,000 lives since 1999. While opioids work by activating the reward centers in the brain, VX-548 works by blocking pain signals at the source.

Vertex plans to file for FDA approval by mid-2024. Analysts estimate VX-548 to bring in peak sales of US$ 5 billion, if approved.

FDA finalizes CAR-T guidance; gene therapies eligible for accelerated approval

Cell therapies have been facing a rough period with narrower funding options that have forced many startups in the biotech sector to shut shop. Last week, FDA issued letters to six manufacturers of cancer therapies that use CAR-T technology to add a boxed warning on their label after the agency found a serious risk of developing secondary cancer associated with them. This warning may raise further concerns over CAR-T therapies.

But now, FDA has stepped in and finalized guidance for companies and academic researchers working on CAR-T cell therapies. The guidance enlists the clinical, non-clinical and manufacturing expectations the agency has before a premarket approval (PMA) application is made. FDA also said gene editing therapies are eligible for accelerated approval and detailed the information that should be provided in an investigational new drug (IND) application.

Approves faster manufacturing of Yescarta: FDA has approved a new manufacturing process for Gilead-owned Kite Pharma’s Yescarta (axicabtagene ciloleuce l). The turnaround time for the therapy has now been reduced to 14 days from 16. This gives it an edge over its competitor, BMS’ Breyanzi (lisocabtagene maraleucel), which targets a turnaround time of 24 days.

Regeneron buys 2seventy bio’s pipeline: Cancer cell therapy company 2seventy b io has decided to sell all its preclinical and clinical programs to Regeneron. It will now focus on its sole approved product Abecma (idecabtagene vicleucel). About 160 2seventy bio employees who support the acquired programs will join Regeneron Cell Medicines, a newly formed research and development unit to advance cell therapies and combination approaches in oncology and immunology.

Pfizer ekes out surprise Q4 2023 profit after announcing thousands of job cuts

Pfizer’s full year results for 2023 were being watched closely, given that its record US$ 100 billion revenue for 2022 wasn’t sustainable with the pandemic receding. The New York-based drugmaker’s 2023 revenue fell 42 percent year-on-year to US$ 58.5 billion due to a sharp drop in Comirnaty and Paxlovid sales. Furthermore, its Q4 2024 revenue of US$ 14.25 billion was lower than Wall Street predictions of US$ 14.42 billion. Yet, Pfizer managed to eke out a profit of US$ 593 million in Q4, when analysts were expecting a US$ 1.1 billion loss.

Pfizer has been tightening its belt for sometime now, and had announced over a thousand job cuts on both sides of the Atlantic. The drug behemoth says it’s on track to deliver at least US$ 4 billion in yearly cost savings by the end of 2024, thanks to its “cost realignment program.” That said, Pfizer also saw a record nine molecules being approved by the FDA in 2023. It also won seven novel drug approvals last year, more than double the number of any other company.

Novavax to reduce workforce by 12 percent: Another drugmaker facing post-Covid blues is Novavax. It plans to reduce its workforce by 12 percent, bringing its total reduction in workforce since Q1 2023 to 30 percent. The cash-strapped biotech is now concentrating its efforts on an updated Covid vaccine and a Covid and flu combination vaccine.

BMS’ Opdivo disappoints, Merck’s Keytruda scores win in kidney cancer trials

BMS has said its PD-1 blocker Opdivo (nivolumab) has failed to meet its primary endpoint of disease-free survival in a late-stage trial in patients with localized renal cell carcinoma who have a high risk of relapse after surgery. The difference between the Opdivo group and the placebo group in terms of efficacy was not noteworthy and the treatment-related adverse events in the former were more. Interestingly, a day prior to this announcement, its rival Merck’s blockbuster PD-1 inhibitor Keytruda (pembrolizumab) showed remarkable clinical benefit for the very same indication. Opdivo as a subcutaneous form, however, did demonstrate non-i nferi or efficacy and safety compared to its intravenous formulation.

Biogen ends post-approval study on Aduhelm to focus on Leqembi

Eisai -Biogen’s first drug to treat Alzheimer’s disease, Aduhelm, faced problems soon after it bagged FDA’s accelerated approval in 2021 with questions being raised about the evidence of patient benefit. Biogen abandoned the drug in 2022 after Medicare limited its coverage. Now, Biogen is ending a post-approval study of Aduhelm, and will focus on its other Alzheimer's medicine Leqembi, also developed along with Eisai. Leqembi bagged FDA approval last year, and has the ability to slow cognitive decline in early Alzheimer's patients.

The PharmaCompass Newsletter – Sign Up, Stay Ahead

Feedback, help us to improve. Click here

Image Credit : Phisper Infographic by PharmaCompass license under CC BY 2.0

“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”

NEWS

DRUGS & DEVELOPMENTS

MARKET INTEL by PharmaCompass

Vertex’s non-opioid painkiller succeeds in two late-stage trials

FDA finalizes CAR-T guidance; gene therapies eligible for accelerated approval

Pfizer ekes out surprise Q4 2023 profit after announcing thousands of job cuts

BMS’ Opdivo disappoints, Merck’s Keytruda scores win in kidney cancer trials

Biogen ends post-approval study on Aduhelm to focus on Leqembi